RUNX2 and ocular melanoma: Then, we explored the effects of DHM in hVICs and found that DHM treatment significantly negated the OM-induced increase in both the mRNA (Figure 1D) and protein (Figures 1E–G) levels of two known osteogenesis-specific genes (ALP and Runx2).